Abstract
In the treatment of human neoplasia, major biological problems present obstacles which make the cure of human cancer difficult. These problems center around the heterogeneous nature of a tumor cell population and the invasive and metastatic potential of this tumor cell population (1–3). The major forms of cancer treatment involve the modalities of surgery, radiation therapy and chemotherapy. In many cases, combinations of these treatment-forms are used sequentially in an attempt to deal with the problems of metastasis and heterogeneity of tumor cells. Results of current research suggest that biotherapy (use of immune regulators, differentiation inducers, etc.) may also provide an additional mode of treatment.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
I. R. Hart and I. J. Fidler, The Implications of Tumor Heterogeneity for Studies on the Biology and Therapy of C aicer Metastases, Biochim. Biophys. Acta 651: 37 (1981).
D. L. Dexter and P. Calabresi, Intraneoplastic Diversity, Biochim. Biophys. Acta 695: 97 (1982).
G. Poste, Pathogenesis of Metastatic Disease: Implications for Current Therapy and for the Development of New Therapeutic Strategies, Cancer Treat. Rep. 70: 183 (1986).
A. C. Sartorelli and W. A. Creasey, Combination Chemotherapy, in: “Cancer Medicine,” J. F. Holland and E. Frei, III, eds., Lea and Febiger, Philadelphia (1982).
R. H. Blum and E. Frei, III, Combination Chemotherapy, in: “Methods in Cancer Research,” Volume XVII, V. T. DeVita, Jr., and H. Busch, eds., Academic Press, New York (1979).
R. E. Wittes and A. Goldin, Unresolved Issues in Combination Chemotherapy, Cancer Treat. Rep. 70: 105 (1986).
G. A. Curt, N. J. Clendeninn, and B. A. Chabner, Drug Resistance in Cancer, Cancer Treat. Rep. 68: 87 (1984).
E. Frei, III, Curative Cancer Chemotherapy, Cancer Res. 45: 6523 (1985).
J. G. Cory and A. Sato, Regulation of Ribonucleotide Reductase Activity in Mammalian Cells, Mol. Cell. Biochem. 53 /54: 257 (1983).
J. G. Cory, Role of Ribonucleotide Reductase in Cell Division, Pharmac. Therap. 21: 265 (1983).
J. G. Cory, A. E. Fleischer, and J. B. Munro, III, Reconstitution of the Ribonucleotide Reductase Enzyme from Ehrlich Tumor Cells, J. Biol. Chem. 253: 2898 (1978).
J. G. Cory and A. E. Fleischer, Noncoordinate Changes in the Components of Ribonucleotide Reductase in Mammalian Cells, J. Biol. Chem. 257: 1263 (1982).
J. G. Cory and A. E. Fleischer, Specific Inhibitors Directed at the Individual Components of Ribonucleotide Reductase as an Approach to Combination Chemotherapy, Cancer Res. 39: 4600 (1979).
J. G. Cory, A. Sato, and L. Lasater, Specific Inhibition of the Subunits of Ribonucleotide Reductase as a New Approach to Combination Chemotherapy, Adv. Enz. Reg. 19: 139 (1981).
R. C. Jackson, The Regulation of Thymidylate Biosynthesis in Novikoff Hepatoma Cells and the Effects of Amethopterin, 5-Fluorodeoxyuridine, and 3-Deazauridine, J. Biol. Chem. 253: 7440 (1978).
J. G. Cory, D. A. Rey, G. L. Carter, and P. E. Bacon, Nucleoside 5’-Diphosphates as Effectors of Mammalian Ribonucleotide Reductase, J. Biol. Chem. 260: 1201 (1985).
R. C. Jackson, A Kinetic Model of Regulation of the Deoxyribonucleoside Triphosphate Pool Composition, Pharmac. Therap. 24: 279 (1984).
J. G. Cory and G. L. Carter, Drug Action on Ribonucleotide Reductase, Adv. Enz. Reg. 24: 385 (1986).
J. A. Montgomery, The Biological Bases for the Design of Anticancer Agents, in: “Cancer Biology and Therapeutics,” J. G. Cory and A. Szentivanyi, eds., Plenum Press, New York (1986).
H. L. Elford, B. Van’t Riet, G. L. Wampler, A. L. Lin, and R. M. Elford, Regulation of Ribonucleotide Reductase in Mammalian Cells by Chemotherapeutic Agents, Adv. Enz. Reg. 19: 151 (1981).
J. G. Cory, G. L. Carter, P. E. Bacon, A. T’ang, and E. J. Lien, Inhibition of Ribonucleotide Reductase and L1210 Cell Growth by NHydroxy-N’-Aminoguanidine Derivatives, Biochem. Pharm. 34: 2645 (1985).
A. C. Sartorelli, K. C. Agarwal, and E. C. Moore, Mechanism of Inhibition of Ribonucleotide Diphosphate Reductase by a-(N)-Heterocyclic Aldehyde Thiosemicarbazones, Biochem. Pharm. 20: 3119 (1971).
J. G. Cory, A. Sato, P. E. Bacon, and D. A. Rey, Nucleoside 5’-Triphosphate Analogs as Positive and Negative Inhibitors of Mammalian Ribonucleotide Reductase, Cancer Biochem. Biophys. 8: 23 (1985).
J. G. Cory, L. Lasater, and A. Sato, Effects of Iron-Chelating Agents on Inhibitors of Ribonucleotide Reductase, Biochem. Pharm. 30: 979 (1984).
A. Sato, J. A. Montgomery, and J. G. Cory, Synergistic Inhibition of Leukemia L1210 Cell Growth In Vitro by Combinations of 2-Fluoroadenine Nucleosides and Hydroxyurea or 2,3-Dihydro-1 H-pyrazole [2,3-a] imidazole, Cancer Res. 44: 3286 (1984).
H. J. Schaeffer and C. F. Schwender, Bridging Hydrophobic and Hydrophilic Regions of Adenosine Deaminase with Some 9-(2-hydroxy-3alkyl) Adenines, J. Med. Chem. 17: 6 (1974).
J. A. Montgomery, The Chemistry and Biology of Nucleosides of Purines and Ring Analogs, in: “Proceedings of the Fifth International Roundtable on Nucleosides, Nucleotides, and their Biological Applications,” Academic Press, New York (1983).
J. D. Stoeckler, C. Canbor, V. Kuhns, S-H. Chu, and R. E. Parks, Jr., Inhibitors of Purine Nucleoside Phosphorylase C(8) and C(5’) Substitutions, Biochem. Pharm. 31: 163 (1982).
I. S. Kazmers, B. S. Mitchell, P. E. Dadonna, L. L. Wotring, L. B. Townsend, and W. B. Kelley, Inhibition of Purine Nucleoside Phosphorylase by 8-Aminoguanosine: Selective Toxicity for T-Lymphoblasts, Science 214: 1137 (1981).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer Science+Business Media New York
About this chapter
Cite this chapter
Cory, J.G. (1987). Site-Directed Combination Chemotherapy. In: Cory, J.G., Szentivanyi, A. (eds) Cancer Biology and Therapeutics. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9564-6_7
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9564-6_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9566-0
Online ISBN: 978-1-4757-9564-6
eBook Packages: Springer Book Archive